KCT0008320
Not yet recruiting
未知
An exploratory study on the safety and efficacy of upper extremity motor function recovery after neuromodulatory stimulation of the contralateral primary motor cortex (M1 cortex) using low-intensity focused ultrasound (NS-US200) in patients with subacute ischemic stroke
ConditionsDiseases of the circulatory system
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Diseases of the circulatory system
- Sponsor
- Korea University Anam Hospital
- Enrollment
- 12
- Status
- Not yet recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\) Adult men and women aged 19 or older but less than 85
- •2\) Patients diagnosed with supratentorial stroke through brain MRI due to their first ischemic stroke, which can affect upper limb function by invading the cortical or subcortical area of the brain, regardless of the occurrence mechanism of ischemic strokes, such as thrombotic, embolic, or lacunar stroke, According to the Korean Clinical Practice Guidelines for Stroke Rehabilitation, repetitive transcranial magnetic stimulation (rTMS) is recommended to improve upper\-limb function after stroke rehabilitation. But it isn't clear who should use rTMS or how well it works for stroke rehabilitation based on where the lesion is or what caused the stroke. Caution should be used because there are some risks and side effects. Low\-intensity focused ultrasound stimulation is considered valid for stroke patients with lesions affecting upper limb function. This is because it is hard to find a single cause for a stroke, and previous studies and guidelines have focused on the functional impairment of upper\-limb function rather than the location of the lesion.
- •3\) Patients in the subacute phase, within three months of an ischemic stroke, based on the screening time, which is when the maximum neural plasticity of the brain occurs after a stroke.
- •4\) Patients with persistent hemiparetic motor impairment due to ischemic stroke at the time of screening: specifically, patients who are evaluated to have muscle weakness at the trunk or proximal part of the affected upper limb with a grade of 4 (good grade) or less according to the manual muscle test performed by a physical therapist are targeted.
- •º 0 grade: no muscle contraction
- •º 1 grade: visible or palpable muscle contraction, but the joint movement is impossible
- •º 2 grade: active joint movement in a gravity\-free state
- •º 3 grade: active joint movement against gravity
- •º 4 grade: active joint movement against gravity and some resistance
- •º 5 grade: active normal joint movement against gravity and full resistance
Exclusion Criteria
- •1\.Patients with grade 5 upper limb muscle strength without significant upper limb muscle weakness after a stroke.
- •2\.Pregnant or breastfeeding women (if a woman of childbearing potential has a positive urine HCG test).
- •3\.Patients with abnormalities of the cerebral hemisphere or a history of cerebral disorders, including cerebrospinal fluid stenosis, brain tumors, abscesses, hydrocephalus, trauma, skull fractures, or congenital brain malformations, observed on brain imaging tests (CT or MRI), other than ischemic stroke.
- •4\.Patients who have undergone baseline blood tests, including the following ranges: ? Kidney disease (creatinine\> 2\.0 mg/dL) ? Thrombocytopenia (less than 100 x 103/µL) ? Leukopenia (less than 4\.0 x 103/µL) ? Liver disease (AST, ALT, total bilirubin values are more than twice the upper limit of the normal range)
- •5\.Uncontrollable cardiac disease patients (unstable congestive heart failure, myocardial infarction, ventricular tachycardia, or third\-degree atrioventricular block)
- •6\.Patients with a history of contact dermatitis or sensitive skin abnormalities.
- •7\.Patients with implanted electronic medical devices such as pacemakers that prevent magnetic resonance imaging (MRI) scanning.
- •8\.Patients with a history of epilepsy, Parkinson's disease, agoraphobia, or other psychiatric disorders.
- •9\.Patients who have a history of taking or are currently taking drugs that affect the peripheral or central nervous system for purposes other than improving cognitive function after a stroke.
- •10\.Patients with the unstable general condition due to current infectious diseases such as fever.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 2
An exploratory study of the safety and efficacy of disulfiram in progressive fibrosing interstitial lung diseaseprogressive fibrosing interstitial lung diseaseinterstitial lung diseaseD017563JPRN-jRCTs031220648rushiyama Hirokazu10
Recruiting
Not Applicable
An exploratory study on the efficacy and safety of Hangesyasinto (TJ-14) for DCF chemotherapy or DCF-RT chemoradiotherapy induced diarrhea in the patients with advanced esophageal cancer.JPRN-UMIN000023825Dokkyo Medical University24
Recruiting
Not Applicable
A exploratory study of the efficacy and safety of oxaliplatin in combination with S-1 in the treatment of non-resectable gastric cancernon-resectable gastric cancer or reccurent gastric cancerJPRN-UMIN000002463niversity of Tokyo Hospital20
Completed
Not Applicable
An exploratory study of the efficacy and safety of yokukansan for postoperative delirium in patients who underwent surgical resection of malignant tumor of digestive system.Digestive system cancerJPRN-UMIN000013235Hitachi,Ltd.,Hitachi General Hospital40
Active, not recruiting
Not Applicable
An Exploratory Study of the Safety and Efficacy of Prophylactic Immunomodulatory Treatment in Myozyme-naive Cross-Reacting Immunologic Material (CRIM[-]) Patients With Infantile-Onset Pompe DiseasePompe disease (acid alpha-glucosidase deficiency)MedDRA version: 17.1Level: LLTClassification code 10036143Term: Pompe's diseaseSystem Organ Class: 100000004850Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]EUCTR2015-000584-14-Outside-EU/EEAGenzyme Corporation Inc4